• In February 2026, Xylem Inc.’s board declared an 8% increase in its first-quarter dividend to US$0.43 per share, payable on March 24, 2026 to shareholders of record on February 24, 2026, alongside reporting full-year 2025 revenue of US$9.04 billion and net income of US$957 million.
• At the same time, Xylem issued cautious 2026 guidance, projecting reported revenue of about US$9.10 billion to US$9.20 billion and modest organic growth as it intentionally exits lower-margin business and faces weaker demand in certain water-treatment markets.
• Next, we’ll examine how Xylem’s softer 2026 revenue outlook and portfolio “walkaways” may influence the company’s broader investment narrative.

This technology could replace computers: discover 23 stocks that are working to make quantum computing a reality.

Xylem Investment Narrative Recap

To own Xylem today, you need to believe in its role as a focused water-technology platform that can trade near-term revenue moderation for higher-quality earnings. The key near-term catalyst is execution on its transformation program, while the biggest risk is that deliberate portfolio “walkaways” and weaker water-treatment demand weigh more heavily on revenue than expected. The latest 2026 guidance reinforces, rather than changes, that balance of opportunity and risk.

The most relevant update is Xylem’s 2026 outlook for US$9.10 billion to US$9.20 billion in revenue, only modestly above 2025’s US$9.04 billion. Management expects low single-digit organic growth as it exits lower-margin business and integrates prior changes, which directly ties into the main catalyst: proving that a “quality over volume” approach can support margin expansion without materially shrinking the company’s long-term opportunity set.

But this also means investors should be very aware of how Xylem’s decision to walk away from lower-margin revenue could interact with already-soft demand in key markets and...

Xylem's narrative projects $10.2 billion revenue and $1.4 billion earnings by 2028. This requires 5.2% yearly revenue growth and around a $462 million earnings increase from $938.0 million today.

Uncover how Xylem's forecasts yield a $167.41 fair value, a 31% upside to its current price.

Exploring Other Perspectives

Some analysts were far more optimistic before this update, assuming revenue could reach about US$10.1 billion and earnings US$1.4 billion by 2028, yet today’s softer guidance and the risk that integration hurdles undercut those ambitions show how widely views can differ and why you should compare these contrasting narratives for yourself.

Explore 4 other fair value estimates on Xylem - why the stock might be worth as much as 31% more than the current price!

Build Your Own Xylem Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Xylem research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Xylem research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Xylem's overall financial health at a glance.

Searching For A Fresh Perspective?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Capitalize on the AI infrastructure supercycle with our selection of the 34 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• AI is about to change healthcare. These 25 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Uncover the next big thing with 28 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.